This Clevecord market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period was driven by factors such as increased awareness of cord blood banking, a rise in the use of umbilical cord blood for treating HIV, expanded insurance coverage for stem cell treatments, advancements in personalized medicine and targeted therapies, and a surge in scientific publications highlighting stem cell efficacy.
In the forecast period, growth is expected to be fueled by an increasing number of cord blood donations, the expanding use of stem cells in regenerative medicine, a global rise in hematopoietic stem cell transplantations, growing adoption of cord blood for treating pediatric and adult leukemia, and ongoing clinical studies on neurodegenerative diseases. Key trends anticipated include advancements in cellular therapies, the expansion of stem cell research to address new diseases, clinical trials focusing on autoimmune disorders, increased public and private investment in stem cell research, and broader utilization of cord blood for treating blood disorders.
The growing demand for stem cell therapies is anticipated to drive the growth of the clevecord market in the future. Stem cell therapy involves using stem cells to repair or replace damaged tissues or cells to treat a variety of conditions, such as blood disorders, neurodegenerative diseases, and injuries. The demand for stem cell therapies is increasing due to factors such as advancements in regenerative medicine, the rise of personalized medicine, greater public awareness, and technological improvements. Clevecord is used in stem cell therapies due to its high mesenchymal stem cell content, which aids in tissue regeneration, immune modulation, and advanced therapeutic applications. For example, in January 2024, the Bioindustry Association (BIA), a UK-based trade organization for life sciences and biotech, reported that the UK continues to be the leading center for clinical trials in cell and gene therapy in Europe, with 84 drugs in development, outpacing France (45), Spain (44), and Germany (40). On a global scale, US companies secured 86% of the venture funding for cell and gene therapy in 2022 and are expected to continue leading in 2023. Therefore, the rising demand for stem cell therapies is contributing to the growth of the clevecord market.
The increasing healthcare expenditure is expected to fuel the growth of the clevecord market. Healthcare expenditure refers to the total amount of resources spent on healthcare services, products, and related activities, such as prevention, diagnosis, treatment, and management of health conditions. This expenditure is rising due to factors such as an aging population, advancements in medical technology, the growing prevalence of chronic diseases, and the rising costs of pharmaceuticals and medical services. Rising healthcare expenditure benefits cleveCord by driving advancements in cord blood banking, supporting innovative medical therapies, and ensuring access to high-quality stem cell storage solutions. For example, in December 2023, the U.S. Centers for Medicare & Medicaid Services, a US-based federal agency, reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, surpassing the 3.2% growth rate in 2021. Clinical and physician services saw a 2.7% increase, totaling $884.9 billion, while retail prescription drug spending rose significantly by 8.4%, reaching $405.9 billion. Therefore, the increasing healthcare expenditure is promoting the growth of the clevecord market.
The growing global aging population is expected to further boost the growth of the clevecord market. The aging population refers to a demographic group with a higher proportion of individuals aged 65 and older, largely due to longer life expectancy and declining birth rates. This population is increasing because of improvements in healthcare and living standards, which have extended life expectancy, along with lower birth rates in many regions. The aging population requires clevecord as stem cell therapies using hematopoietic progenitor cells from cord blood can treat age-related blood disorders, cancers, and degenerative diseases, offering regenerative solutions for older individuals with weakened immune systems and diminished cell regeneration capacity. For example, in October 2024, the World Health Organization (WHO) projected that the number of people aged 60 and older will rise from 1 billion in 2020 to 1.4 billion by 2030, representing one in six of the global population. By 2050, this number is expected to double to 2.1 billion, with the number of people aged 80 and older predicted to triple, reaching 426 million. As a result, the increasing global aging population is driving the growth of the clevecord market.
The key company operating in the clevecord market is Cleveland Cord Blood Center Inc.
North America was the largest region in the clevecord market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in clevecord report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the clevecord market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Clevecord is a stem cell product derived from umbilical cord blood, primarily used in hematopoietic stem cell transplantation. It is intended for patients with hematopoietic system disorders, such as leukemia or lymphoma, particularly when a suitable unrelated donor is available. The product contains hematopoietic progenitor cells, which play a vital role in blood and immune system recovery following intensive treatments such as chemotherapy.
The primary indications for clevecord include chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Chronic myeloid leukemia is a type of cancer originating in the bone marrow that affects the blood, marked by the abnormal proliferation of white blood cells. Clevecord is distributed through hospital, retail, and specialty pharmacies and is utilized across various settings, including hospitals, clinics, ambulatory care facilities, and home care environments.
The clevecord market research report is one of a series of new reports that provides clevecord market statistics, including clevecord industry global market size, regional shares, competitors with a clevecord market share, detailed clevecord market segments, market trends and opportunities, and any further data you may need to thrive in the clevecord industry. This clevecord market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The clevecord market consists of sales of ex vivo stem cell expansion kits, hematopoietic stem cell products, stem cell-derived wound healing products and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period was driven by factors such as increased awareness of cord blood banking, a rise in the use of umbilical cord blood for treating HIV, expanded insurance coverage for stem cell treatments, advancements in personalized medicine and targeted therapies, and a surge in scientific publications highlighting stem cell efficacy.
In the forecast period, growth is expected to be fueled by an increasing number of cord blood donations, the expanding use of stem cells in regenerative medicine, a global rise in hematopoietic stem cell transplantations, growing adoption of cord blood for treating pediatric and adult leukemia, and ongoing clinical studies on neurodegenerative diseases. Key trends anticipated include advancements in cellular therapies, the expansion of stem cell research to address new diseases, clinical trials focusing on autoimmune disorders, increased public and private investment in stem cell research, and broader utilization of cord blood for treating blood disorders.
The growing demand for stem cell therapies is anticipated to drive the growth of the clevecord market in the future. Stem cell therapy involves using stem cells to repair or replace damaged tissues or cells to treat a variety of conditions, such as blood disorders, neurodegenerative diseases, and injuries. The demand for stem cell therapies is increasing due to factors such as advancements in regenerative medicine, the rise of personalized medicine, greater public awareness, and technological improvements. Clevecord is used in stem cell therapies due to its high mesenchymal stem cell content, which aids in tissue regeneration, immune modulation, and advanced therapeutic applications. For example, in January 2024, the Bioindustry Association (BIA), a UK-based trade organization for life sciences and biotech, reported that the UK continues to be the leading center for clinical trials in cell and gene therapy in Europe, with 84 drugs in development, outpacing France (45), Spain (44), and Germany (40). On a global scale, US companies secured 86% of the venture funding for cell and gene therapy in 2022 and are expected to continue leading in 2023. Therefore, the rising demand for stem cell therapies is contributing to the growth of the clevecord market.
The increasing healthcare expenditure is expected to fuel the growth of the clevecord market. Healthcare expenditure refers to the total amount of resources spent on healthcare services, products, and related activities, such as prevention, diagnosis, treatment, and management of health conditions. This expenditure is rising due to factors such as an aging population, advancements in medical technology, the growing prevalence of chronic diseases, and the rising costs of pharmaceuticals and medical services. Rising healthcare expenditure benefits cleveCord by driving advancements in cord blood banking, supporting innovative medical therapies, and ensuring access to high-quality stem cell storage solutions. For example, in December 2023, the U.S. Centers for Medicare & Medicaid Services, a US-based federal agency, reported that U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, surpassing the 3.2% growth rate in 2021. Clinical and physician services saw a 2.7% increase, totaling $884.9 billion, while retail prescription drug spending rose significantly by 8.4%, reaching $405.9 billion. Therefore, the increasing healthcare expenditure is promoting the growth of the clevecord market.
The growing global aging population is expected to further boost the growth of the clevecord market. The aging population refers to a demographic group with a higher proportion of individuals aged 65 and older, largely due to longer life expectancy and declining birth rates. This population is increasing because of improvements in healthcare and living standards, which have extended life expectancy, along with lower birth rates in many regions. The aging population requires clevecord as stem cell therapies using hematopoietic progenitor cells from cord blood can treat age-related blood disorders, cancers, and degenerative diseases, offering regenerative solutions for older individuals with weakened immune systems and diminished cell regeneration capacity. For example, in October 2024, the World Health Organization (WHO) projected that the number of people aged 60 and older will rise from 1 billion in 2020 to 1.4 billion by 2030, representing one in six of the global population. By 2050, this number is expected to double to 2.1 billion, with the number of people aged 80 and older predicted to triple, reaching 426 million. As a result, the increasing global aging population is driving the growth of the clevecord market.
The key company operating in the clevecord market is Cleveland Cord Blood Center Inc.
North America was the largest region in the clevecord market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in clevecord report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the clevecord market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Clevecord is a stem cell product derived from umbilical cord blood, primarily used in hematopoietic stem cell transplantation. It is intended for patients with hematopoietic system disorders, such as leukemia or lymphoma, particularly when a suitable unrelated donor is available. The product contains hematopoietic progenitor cells, which play a vital role in blood and immune system recovery following intensive treatments such as chemotherapy.
The primary indications for clevecord include chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Chronic myeloid leukemia is a type of cancer originating in the bone marrow that affects the blood, marked by the abnormal proliferation of white blood cells. Clevecord is distributed through hospital, retail, and specialty pharmacies and is utilized across various settings, including hospitals, clinics, ambulatory care facilities, and home care environments.
The clevecord market research report is one of a series of new reports that provides clevecord market statistics, including clevecord industry global market size, regional shares, competitors with a clevecord market share, detailed clevecord market segments, market trends and opportunities, and any further data you may need to thrive in the clevecord industry. This clevecord market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The clevecord market consists of sales of ex vivo stem cell expansion kits, hematopoietic stem cell products, stem cell-derived wound healing products and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Clevecord Market Characteristics4. Clevecord Market Trends and Strategies5. Clevecord Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Clevecord Pricing Analysis & Forecasts30. Global Clevecord Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Clevecord Market32. Recent Developments in the Clevecord Market
3. Clevecord Market Biologic Drug Characteristics
6. Global Clevecord Growth Analysis and Strategic Analysis Framework
8. Clevecord Market Segmentation
9. Global Clevecord Epidemiology of Clinical Indications
10. Clevecord Market Regional and Country Analysis
11. Asia-Pacific Clevecord Market
12. China Clevecord Market
13. India Clevecord Market
14. Japan Clevecord Market
15. Australia Clevecord Market
16. South Korea Clevecord Market
17. Western Europe Clevecord Market
18. UK Clevecord Market
19. Germany Clevecord Market
20. France Clevecord Market
21. Eastern Europe Clevecord Market
22. North America Clevecord Market
23. USA Clevecord Market
24. Canada Clevecord Market
25. South America Clevecord Market
26. Middle East Clevecord Market
27. Africa Clevecord Market
28. Clevecord Market Competitive Landscape and Company Profiles
29. Global Clevecord Market Pipeline Analysis
33. Clevecord Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Clevecord Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on clevecord market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for clevecord? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The clevecord market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Chronic Myeloid Leukemia (CML); Gastrointestinal Stromal Tumors (GISTs)2) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Specialty Pharmacies
3) by End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Mentioned: Cleveland Cord Blood Center Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Cleveland Cord Blood Center Inc.
